Wockhardt’s Zaynich antibiotic achieves 97% efficacy against carbapenem-resistant bacteria
Wockhardt Limited announced today that its novel antibiotic Zaynich (Zidebactam/Cefepime, WCK 5222) achieved over 97 per cent clinical efficacy in treating serious infections caused by carbapenem-resistant bacteria. The breakthrough results came from a clinical study conducted across 15 tertiary care hospitals in India.
The shares of Wockhardt Limited were trading at ₹1,319.55 down by ₹68.60 or 4.94 per cent on the NSE today at 3.12 pm.
The drug demonstrated 100 per cent efficacy in treating bloodstream infections, hospital-acquired bacterial pneumonia, and complicated intra-abdominal infections, while showing 97.3 per cent success rate in complicated urinary tract infections. The study targeted patients with confirmed carbapenem-resistant infections identified through rapid molecular diagnostic technologies.
Zaynich’s performance is particularly significant given the currently limited treatment options for carbapenem-resistant infections, which typically rely on toxic alternatives like colistin and polymyxins. The study included critically ill patients with various severe infections, with 17 per cent of participants having concurrent bloodstream infections.
The drug is in the final stages of a multi-national Phase III study for global marketing authorization. It has previously received Qualified Infectious Disease Product status from the US FDA, along with five other products in Wockhardt’s portfolio.
Wockhardt employs approximately 2,600 people across 27 nationalities and maintains research and manufacturing facilities in India, the USA, the UK, and Ireland. Seventy-nine per cent of its global revenue comes from international operations.
